Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 4.31%61.61B | 1.93%41.83B | -2.06%22.47B | -0.69%74.99B | 1.50%59.06B | 2.68%41.04B | 6.09%22.95B | 6.68%75.52B | 6.16%58.18B | 7.39%39.97B |
| Operating income | 4.31%61.61B | 1.93%41.83B | -2.06%22.47B | -0.69%74.99B | 1.50%59.06B | 2.68%41.04B | 6.09%22.95B | 6.68%75.52B | 6.16%58.18B | 7.39%39.97B |
| Operating expenses | -4.44%-50.76B | -2.79%-34.17B | 0.02%-17.86B | -1.87%-62.47B | -4.49%-48.6B | -5.05%-33.24B | -7.68%-17.87B | -6.64%-61.33B | -5.79%-46.51B | -7.22%-31.65B |
| Gross profit | 3.72%10.85B | -1.74%7.66B | -9.24%4.61B | -11.75%12.52B | -10.40%10.46B | -6.32%7.8B | 0.87%5.08B | 6.85%14.19B | 7.68%11.67B | 8.04%8.32B |
| Selling expenses | -2.01%-4.32B | 2.92%-3.03B | 15.97%-1.59B | 7.95%-5.62B | 10.13%-4.23B | 4.40%-3.12B | -1.21%-1.89B | -3.90%-6.1B | -5.51%-4.71B | -2.42%-3.26B |
| Administrative expenses | -1.85%-1.79B | 0.89%-1.2B | 5.92%-605.95M | 0.57%-2.41B | 0.76%-1.76B | -1.12%-1.21B | -2.34%-644.08M | -9.16%-2.42B | -11.89%-1.77B | -12.31%-1.2B |
| Research and development expenses | 23.30%-443.72M | 27.06%-285.29M | 22.79%-143.71M | 2.35%-763.77M | 0.17%-578.51M | 2.35%-391.15M | -3.76%-186.14M | 4.55%-782.14M | 12.78%-579.48M | 9.23%-400.57M |
| Profit from asset sales | 480.24%4.25M | 1,139.80%3.63M | 514.04%142.96K | -7.55%11.12M | -52.07%733.1K | -33.40%293K | -93.60%23.28K | 1,643.51%12.03M | 73.40%1.53M | -20.73%439.94K |
| Revaluation surplus | -135.23%-9.9M | -2,662.43%-11.42M | -216.45%-9.6M | -36.19%24.65M | 31.79%28.11M | -98.99%445.75K | -41.05%8.24M | 1,175.97%38.64M | 491.21%21.33M | 4,726.36%44.05M |
| -Changes in the fair value of other assets | -135.23%-9.9M | -2,662.43%-11.42M | -216.45%-9.6M | -36.19%24.65M | 31.79%28.11M | -98.99%445.75K | -41.05%8.24M | 1,175.97%38.64M | 491.21%21.33M | 4,726.36%44.05M |
| Impairment and provision | -119.99%-203.82M | -85.87%-155.1M | -23.78%-94.4M | -442.99%-470.58M | 31.34%-92.65M | 13.50%-83.44M | -0.64%-76.26M | -63.12%-86.67M | -129.60%-134.95M | -340.90%-96.47M |
| -Other impairment is provision | -119.99%-203.82M | -85.87%-155.1M | -23.78%-94.4M | -442.99%-470.58M | 31.34%-92.65M | 13.50%-83.44M | -0.64%-76.26M | -63.12%-86.67M | -129.60%-134.95M | -340.90%-96.47M |
| Special items of operating profit | 19.21%493.7M | 1.44%346.77M | -11.32%213.45M | 5.72%637.09M | -10.44%414.15M | 32.64%341.86M | 103.23%240.71M | -33.16%602.63M | 0.41%462.45M | -31.19%257.75M |
| Adjustment items of operating profit | ---0.05 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Operating profit | 7.84%4.32B | -0.53%3.15B | -6.29%2.28B | -28.75%3.63B | -15.05%4B | -9.37%3.17B | 4.96%2.43B | 3.86%5.1B | 9.63%4.71B | 9.09%3.49B |
| Financing cost | -9,785.73%-201.94M | -306.37%-123.14M | -360.93%-51.95M | -295.44%-38.23M | -104.66%-2.04M | 50.37%59.67M | -43.52%19.91M | -87.96%19.56M | -73.09%43.84M | -69.34%39.68M |
| Adjustment items of earning before tax | 1,287.48%68.95M | 1,831.24%63.89M | 3,876.52%3.62M | 207.57%11.19M | 229.78%4.97M | 653.48%3.31M | -95.91%91.02K | 66.62%-10.4M | 11.74%-3.83M | -349.72%-597.68K |
| Earning before tax | 4.44%4.18B | -4.30%3.09B | -9.03%2.23B | -29.41%3.61B | -15.71%4.01B | -8.59%3.23B | 4.13%2.45B | 1.33%5.11B | 6.63%4.75B | 6.02%3.53B |
| Tax | -9.68%-785.98M | 8.35%-514.49M | 11.19%-373.54M | 28.70%-606.85M | 13.00%-716.6M | 8.11%-561.37M | -8.99%-420.62M | -7.76%-851.17M | -6.67%-823.71M | -4.74%-610.95M |
| After-tax profit from continuing operations | 3.30%3.4B | -3.45%2.58B | -8.58%1.86B | -29.55%3B | -16.27%3.29B | -8.68%2.67B | 3.18%2.03B | 0.14%4.26B | 6.62%3.93B | 6.29%2.92B |
| Earning after tax | 3.30%3.4B | -3.45%2.58B | -8.58%1.86B | -29.55%3B | -16.27%3.29B | -8.68%2.67B | 3.18%2.03B | 0.14%4.26B | 6.62%3.93B | 6.29%2.92B |
| Minority profit | -32.50%88.07M | -49.54%59.78M | -50.91%36.14M | -18.86%165.24M | -5.10%130.46M | 7.21%118.47M | 21.76%73.61M | -29.00%203.65M | -34.65%137.48M | -30.48%110.49M |
| Profit attributable to shareholders | 4.78%3.31B | -1.31%2.52B | -6.99%1.82B | -30.09%2.84B | -16.68%3.16B | -9.31%2.55B | 2.59%1.96B | 2.25%4.06B | 9.12%3.79B | 8.54%2.81B |
| Basic earnings per share | 4.79%2.036 | -1.28%1.548 | -6.98%1.12 | -30.10%1.744 | -16.68%1.943 | -9.31%1.568 | 2.56%1.204 | 2.25%2.495 | 9.12%2.332 | 8.54%1.729 |
| Diluted earnings per share | 4.79%2.036 | -1.28%1.548 | -6.98%1.12 | -30.10%1.744 | -16.68%1.943 | -9.31%1.568 | 2.56%1.204 | 2.25%2.495 | 9.12%2.332 | 8.54%1.729 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.